Supreme Court: Complex Biotechnology Patent Validity Cannot Be Decided Summarily Without Trial and Expert Evidence

Aadrikaa Legal Services (ALS)- Law I Litigation I Arbitration

Date: 12.09.2026

Supreme Court: Complex Biotechnology Patent Validity Cannot Be Decided Summarily Without Trial and Expert Evidence

In a significant ruling concerning patent protection for biotechnology, genetically modified cotton technology and the scope of Section 3(j) of the Patents Act, 1970, the Supreme Court set aside the Delhi High Court Division Bench judgment that had effectively decided Monsanto’s patent validity against it at the interim stage.

The Supreme Court held that technically complex questions concerning patentability, patent exclusion and biotechnology cannot be summarily adjudicated without a full trial, evidence and expert testimony. It restored the earlier order of the Single Judge and remanded the suit for adjudication in accordance with law.

Importantly, the Supreme Court did not finally decide whether Monsanto’s patent was valid or whether its biotechnology was excluded from patentability under Section 3(j). Those substantive questions were expressly left open for determination in appropriate proceedings on evidence.

Background: Monsanto’s BOLGARD and BOLGARD II Technology

• Monsanto Technology LLC and the other plaintiffs had instituted a commercial suit seeking a permanent injunction against Nuziveedu Seeds Ltd. and others in relation to the trademarks “BOLGARD” and “BOLGARD II” and alleged infringement of registered Patent No. 214436.
• Monsanto also sought to restrain the defendants from selling or using seeds and hybrid seeds bearing the patented technology, along with rendition of accounts.
• The parties had entered into a sub-licence agreement dated 21 February 2004, initially for ten years. Under the agreement, the defendants were permitted to develop genetically modified hybrid cotton planting seeds using Monsanto’s technology, subject to contractual restrictions and payment of licence fee/trait value.
• Disputes subsequently arose over the payment of licence fee or trait value following the introduction of a statutory price-control regime. Monsanto ultimately terminated the agreement on 14 November 2015 and sought an injunction against continued use of its patented technology.

Nuziveedu Challenges Monsanto Patent Under Section 3(j)

• Nuziveedu contested Monsanto’s claim and relied upon the Protection of Plant Varieties and Farmers’ Rights Act, 2001 (PPVFR Act).
• It also filed a counterclaim seeking revocation of Monsanto’s patent under Section 64 of the Patents Act, arguing that the patent fell within the exclusion contained in Section 3(j) concerning plants, seeds and essentially biological processes.
• This raised a legally and scientifically complex question: whether the patented nucleic acid sequence and associated biotechnology constituted a patentable invention or whether, when incorporated into a plant or seed, it attracted the statutory exclusion under Section 3(j).

Single Judge Says Patent Questions Require Evidence

• At the interim stage, the Delhi High Court’s Single Judge declined to finally determine the validity of the patent.
• In the order dated 28 March 2017, the Single Judge observed that the issues required formal proof and, particularly in a technically complicated patent dispute, expert opinion was crucial for determining the nature and breadth of the monopoly claimed under the patent.
• Pending disposal of the suit, the parties were directed to remain bound by their respective obligations under the sub-licence agreement, with licence fee/trait value governed by the applicable law. Significantly, the Single Judge merely issued notice on Nuziveedu’s counterclaim for revocation; the counterclaim itself was not adjudicated.

Division Bench Rules Against Monsanto on Section 3(j)

• Both sides challenged the Single Judge’s order.
• The Division Bench dismissed Monsanto’s appeal and accepted the defendants’ contention concerning the exclusion from patentability under Section 3(j) of the Patents Act. It held that Monsanto could seek registration under the PPVFR Act and consequently allowed the defendants’ counterclaim.
• The underlying suit was, however, permitted to continue in relation to damages and other reliefs.
• The matter then reached the Supreme Court.

Supreme Court: Division Bench Went Beyond the Injunction Appeal

• The Supreme Court identified a fundamental procedural problem with the Division Bench’s approach.
• The defendants’ counterclaim seeking revocation of the patent had never been adjudicated by the Single Judge; only notice had been issued on it. The Supreme Court found no justification for the Division Bench effectively deciding the validity of the patent in the course of appeals arising from the interim injunction proceedings.
• According to the Supreme Court, the Division Bench ought to have confined itself to deciding whether the interim injunction granted by the Single Judge was justified.
• It should not have assumed the Single Judge’s jurisdiction and proceeded to determine the unpatentability of the claims through a summary exercise.

Patent Disputes Involving Biotechnology Require Expert Evidence

• A particularly important aspect of the judgment is the Supreme Court’s recognition of the technical complexity involved in biotechnology patent litigation.
• The Court noted that the dispute involved questions concerning chemical, biochemical, biotechnological and microbiological processes. Among the questions requiring examination were whether the nucleic acid sequence, once inserted into a plant variety, could subsequently be removed and whether the patented DNA sequence constituted a plant or part of a plant.
• Such questions, the Court held, could not properly be decided merely from pleadings and publicly available documents without evidence from expert witnesses.
• The Court therefore observed that summary adjudication of a technically complex patent suit requiring expert evidence at the injunction stage was neither desirable nor permissible in law.

Section 64 Counterclaim Cannot Be Decided Without Proper Trial

• The Supreme Court also considered the procedural framework for revocation of patents under Section 64 of the Patents Act.
• It held that a counterclaim seeking revocation necessarily requires proper consideration of both the suit and counterclaim in accordance with law. Such a dispute cannot be decided summarily and without evidence merely through an abstract consideration of textbooks or other materials.
• The Court emphasised the importance of ordinary civil trial safeguards, including settlement of issues, examination and cross-examination of witnesses, discovery and inspection of documents, followed by a proper hearing.

Supreme Court: “There Are No Short-Cuts in the Trial of Suits”

• The Supreme Court relied upon Alka Gupta v. Narender Kumar Gupta, (2010) 10 SCC 141, reiterating the fundamental principle that civil litigation ordinarily has to proceed through the procedure prescribed by the Code of Civil Procedure.
• The cited precedent emphasised that courts cannot short-circuit a civil suit by deciding disputed questions of fact merely from pleadings and documents without conducting a trial.
• This principle assumed particular importance in Monsanto’s case because the controversy involved sophisticated scientific questions whose resolution required expert and technical evidence.

Supreme Court Does Not Decide Whether Monsanto’s Patent Is Valid

• One of the most important aspects of the ruling is what the Supreme Court did not decide.
• Despite extensive arguments concerning the Patents Act, the PPVFR Act, WTO obligations, GATT, TRIPS and the technical nature of Monsanto’s biotechnology, the Supreme Court expressly declined to rule upon those substantive issues at this stage.
• The Court stated that, given the nature of the order it proposed to pass, it was unnecessary to determine those questions and accordingly left all questions of fact and law open for consideration in appropriate proceedings.
• Therefore, the judgment should not be interpreted as a final Supreme Court declaration that Monsanto’s Bt cotton patent was either valid or invalid under Section 3(j).
• Rather, the Supreme Court’s ruling was primarily procedural: such a technically complex question had to be decided through a proper trial.

What Were Monsanto’s Patent Claims?

• The judgment records that Claims 1–24 related to processes, whereas Claims 25–27 concerned the chemical product described as a nucleic acid sequence (NAS).
• According to Monsanto, the latter was a man-made DNA construct that did not exist in nature. Monsanto argued that when inserted into a plant, the construct conferred insect-tolerant characteristics upon the plant.
• The competing arguments over whether such technology remained independently patentable or became inseparable from a plant—and therefore potentially subject to Section 3(j)—were precisely the kind of scientific and legal questions the Supreme Court considered inappropriate for summary determination.

Division Bench Judgment Set Aside; Single Judge’s Order Restored

• Ultimately, the Supreme Court set aside the Division Bench judgment.
• The order of the Single Judge dated 28 March 2017 was restored, and the suit was remanded to the Single Judge for disposal in accordance with law. Given the importance of the questions involved, the Supreme Court also expected the parties to cooperate in facilitating an early disposal of the suit.
• The connected appeals and intervention applications were accordingly disposed of.

Who Won the Supreme Court Case?

• In terms of the immediate appellate outcome, Monsanto Technology LLC succeeded before the Supreme Court because the Division Bench judgment that had gone against Monsanto on patentability was set aside.
• However, Monsanto did not obtain a final declaration from the Supreme Court that Patent No. 214436 was valid or that Nuziveedu had infringed it.
• Instead, the Supreme Court restored the Single Judge’s interim arrangement and sent the substantive patent dispute back for trial. Thus, Monsanto succeeded on the issue of improper summary adjudication, while the ultimate questions of patent validity, Section 3(j) exclusion and infringement remained open.

Legal Significance of the Judgment

The judgment is important well beyond the immediate Monsanto-Nuziveedu dispute. It establishes a strong procedural principle for intellectual-property litigation: courts should not finally determine technically complex patent validity questions at an interim stage when those questions require scientific evidence and expert testimony.

It also reinforces the distinction between deciding whether an interim injunction should operate and finally adjudicating a counterclaim for revocation of a patent.

For biotechnology disputes in particular, the judgment recognises that questions involving genetic constructs, biological processes, plant characteristics and patent exclusions cannot necessarily be resolved simply by reading statutory provisions and technical literature. Where competing scientific propositions are involved, those propositions must ordinarily be tested through evidence.

Aadrikaa Legal Services is a trusted legal and regulatory support partner providing end-to-end legal solutions to law firms, corporate organizations, and businesses across India. We specialize in paralegal services, litigation support, tax and regulatory matters, delivering reliable, efficient, and result-oriented legal assistance.

Our services include comprehensive paralegal support, drafting and documentation, legal research, case management, litigation handling, and representation support across various judicial and quasi-judicial forums. We also assist in direct and indirect tax matters, customs, GST, corporate regulatory compliance, and legal advisory.

Source: Supreme Court

Disclaimer

Handy Download:

Write to us at office@aadrikaalaw.com

Tel: +91-11-4999 2707

www.aadrikaalaw.com

Ravi Shekhar Jha – Advocate, Bar Council of Delhi